This thread discusses the unmet medical need for sarcoidosis and the low success rate of steroids as the only option. The company $LIFE has received $20 million from its Japanese partner Kyorin and is eligible to receive additional funding. Data review has shown that the drug ATYR1923 is safe and has a 58% reduction in steroid use from baseline and 22% relative reduction. There has also been a clinically meaningful improvement in dyspnea, cough, and fatigue. The company has been granted U.S. and E.U. orphan drug and U.S. Fast Track designations. The author has accumulated a significant position around $1.7 and is planning to add dips based on market sentiment.

LIFE stock price is None. LIFE 52 Week low is None. LIFE 52 Week high is None. LIFE 200 day moving average is . It is currently trading below 200 day moving average. LIFE 50 day moving average is which is above(bearish) the current price. RSI (relative strength index) of LIFE is which is below (bearish) 70. Chaikin money flow (20 day) of LIFE is which is below (bearish) 0.